DIASORIN LAUNCHES SIMPLEXA GROUP B STREP DIRECT MOLECULAR ASSAY IN THE UNITED STATES

November 19, 2018 - Saluggia (VC) - DiaSorin (FTSE Mid Cap: DIA) announced to have received FDA clearance for its new Simplexa Group B Strep Direct recently launched in the European market.

Designed for use on the LIAISON MDX instrument, the new test enables the direct detection of Group B Streptococcus DNA. The new assay can replace traditional culture testing methods and features an efficient and fast workflow.

GBS infection is a leading cause of early-onset neonatal sepsis. An estimated one in five pregnant women around the world carries GBS bacteria and its vertical transmission to the newborn can result in an invasive infection known as early onset disease (EOD). Infants with EOD will present with fever, lethargy, sepsis, pneumonia and, more rarely, meningitis within the first 24 to 48 hours of life.

The World Health Organization estimates that GBS causes an estimated 150,000 preventable stillbirths and infant deaths every year.

“After the launch few weeks ago in Europe, now the Simplexa Group B Strep Direct is available also in the United States.” said Michelle Tabb, Chief Scientific Officer at DiaSorin Molecular LLC. “Our Group continue to support hospitals and clinical labs worldwide to provide excellent patient care through high-quality molecular assays also in the women’s health testing market all over the world.”

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it